News & Events

Company Completes Enrollment in Phase 2 Clinical Trial Austin, TX – October 6, 2014 – Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the development of AeroVanc, the first inhaled antibiotic being developed to address the growing number of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). Previous investors...
Read more
AUSTIN, TX – December 10, 2013 – Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. The company also received Fast Track designation for AeroVanc pursuant to...
Read more
AUSTIN, TX – December 5, 2013 – Savara Pharmaceuticals announced today that the company has appointed Dr. Joseph S. McCracken, DVM and Yuri Pikover to its Board of Directors. Dr. McCracken has more than 25 years of experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. Most recently he was Global Head of Business Development...
Read more
AUSTIN, TX – October 17, 2013 – Savara Pharmaceuticals announced today it has received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation. The award will advance the development of AeroVanc, the first inhaled antibiotic being developed to treat the increasing number of people with cystic...
Read more
AUSTIN, TX – April 18, 2013 – Savara Pharmaceuticals announced today that the first patient has started study drug treatment in a Phase 2 clinical trial evaluating the safety and efficacy of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. AeroVanc is the first inhaled antibiotic being developed to address the...
Read more